Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Deffered Revenue (2020 - 2022)

Xeris Biopharma Holdings (XERS) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $6.6 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Non-Current Deffered Revenue fell 2.65% year-over-year to $6.6 million, compared with a TTM value of $6.6 million through Sep 2022, down 2.65%, and an annual FY2021 reading of $6.9 million, up 3.83% over the prior year.
  • Non-Current Deffered Revenue was $6.6 million for Q3 2022 at Xeris Biopharma Holdings, down from $6.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $6.9 million in Q1 2022 and bottomed at $6.6 million in Q4 2020.
  • Average Non-Current Deffered Revenue over 3 years is $6.8 million, with a median of $6.8 million recorded in 2021.
  • The sharpest move saw Non-Current Deffered Revenue increased 3.83% in 2021, then dropped 2.65% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $6.6 million in 2020, then rose by 3.83% to $6.9 million in 2021, then fell by 3.46% to $6.6 million in 2022.
  • Business Quant data shows Non-Current Deffered Revenue for XERS at $6.6 million in Q3 2022, $6.8 million in Q2 2022, and $6.9 million in Q1 2022.